FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely phthisiology, and is used for diagnosing the membrane-destructive effect of antituberculous chemotherapy. That is ensured by chromatographic examination of lipid spectrum of blood plasma. Further, in the patients with pulmonary tuberculosis receiving the anti-tuberculosis chemotherapy, the relative content of the blood plasma lysophosphatidylcholine fraction is determined. If values exceed 12 %, the membrane-destructive effect of antituberculosis chemotherapy is diagnosed.
EFFECT: invention can be used for diagnostic purposes for early detection of membrane-destructive effect of anti-tuberculosis chemotherapy and determination of indications for corrective therapy.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING THE CONDITION OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN PULMONARY TUBERCULOSIS PATIENTS | 2019 |
|
RU2709499C1 |
| METHOD FOR INCREASING THE EFFECTIVENESS OF ANTI-TUBERCULOSIS CHEMOTHERAPY | 2020 |
|
RU2751807C1 |
| METHOD FOR TREATMENT OF CASEOUS PNEUMONIA | 2002 |
|
RU2224511C1 |
| METHOD FOR MONITORING THE CONTENT OF ANTI-TUBERCULOSIS PREPARATIONS OF THE MAIN LINE AND THEIR TOXIC METABOLITES IN BLOOD PLASMA | 2018 |
|
RU2702998C1 |
| ANTITUBERCULOUS COMPOSITION AND METHOD FOR PREPARING IT | 2011 |
|
RU2472512C1 |
| METHOD OF DIAGNOSTIC CHECKING OF PULMONARY TUBERCULOSIS | 0 |
|
SU1163263A1 |
| METHOD FOR PREDICTING TREATMENT RESULTS IN INFILTRATIVE PULMONARY TUBERCULOSIS PATIENTS | 2005 |
|
RU2284041C1 |
| METHOD FOR CHOOSING THERAPEUTIC APPROACH FOR PATIENTS WITH NEWLY DIAGNOSED INFILTRATIVE PULMONARY TUBERCULOSIS | 2015 |
|
RU2602683C1 |
| METHOD FOR TREATING DIFFERENT FORMS OF PULMONARY TUBERCULOSIS, RESISTANT TO ANTITUBERCULAR CHEMOTHERAPY, AMONG THEM | 2001 |
|
RU2197984C1 |
| COFORMULATED ANTITUBERCULOUS DRUG | 2009 |
|
RU2430724C2 |
